Cepheid's BCR-ABL Ultra

Cepheid has begun shipping the CE-IVD marked Xpert BCR-ABL Ultra test to quantitate mRNA transcripts in patients with chronic myelogenous leukemia undergoing tyrosine kinase inhibitor treatment. The assay is an updated version of the Xpert BCR-ABL Monitor test that provides increased sensitivity, the firm said. It is aligned to the International Scale on a lot-to-lot basis, increasing reliability of comparisons between labs, and uses the Cepheid GeneXpert system to deliver results in less than two and a half hours.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

What happens to scientific papers when certain journals are no longer published? Some scientists are trying to make sure they don't disappear forever.

A study in Microbiome finds that heavy drinkers have an unhealthy mix of bacteria in their mouths.

Doctors and patients are still trying to figure out what role at-home genetic testing should play in healthcare, Newsweek says.

In Genome Research this week, mismatch repair deficiency in C. elegans, retracing transcriptions start site evolution in the human genome, and more.